On June 5, 2026, the FDA cleared the EyeBOX SNAP from Oculogica, Inc. of New Richmond, Wisconsin, under 510(k) premarket notification number K254086. The device carries an unusually descriptive regulatory name: a brain-injury adjunctive interpretive oculomotor assessment aid. Stripped of the regulatory grammar, that means a device that watches how your eyes move and uses what it sees to help a clinician decide whether you may have a concussion. It is classified Class II under the neurology panel, product code QEA, and was cleared via the Traditional 510(k) pathway with a substantial-equivalence finding.
Concussion has always been one of medicine's frustrating diagnoses precisely because it leaves so little to measure. A broken bone shows on an X-ray; a tumor shows on an MRI. A mild traumatic brain injury frequently shows nothing on conventional imaging, which is why diagnosis has leaned on symptom questionnaires and clinical judgment — inherently subjective, easily confounded by a patient who wants to get back in the game or back to work. The premise behind the EyeBOX SNAP is that the eyes betray what scans cannot. The cranial nerves and brain regions that coordinate eye movement are extensive and sensitive, so a disruption from injury can show up as subtle abnormalities in how the eyes track and move. Turn those movements into data, and you have a signal where there used to be a guess.
The marketing name and the filing name
It is worth pausing on the gap between how a device like this gets described in a press cycle and how the FDA records it. A product announcement will say "objective concussion assessment." The 510(k) record says "adjunctive interpretive oculomotor assessment aid," and every word in that phrase is load-bearing. "Adjunctive" means it supports a clinician's evaluation rather than replacing it. "Interpretive" means it produces an output a clinician reads, not a verdict it issues. "Aid" reinforces the same boundary. The FDA's naming is doing the work of preventing a sensor from being mistaken for a diagnosis. For a consumer trying to understand what one of these devices can actually claim, the filing name is the honest version of the marketing name.
The QEA product code and the 882.1455 regulation it points to are how the agency files this kind of device. The advisory committee is neurology — the panel responsible for devices that touch the brain and nervous system. The decision code, SESE, is the standard substantial-equivalence outcome, meaning the FDA found the EyeBOX SNAP comparable in intended use and safety to a predicate already on the market. That predicate matters: it tells you the agency was not evaluating eye-tracking concussion assessment from a blank slate but against an existing cleared device, which is consistent with Oculogica's history in this exact category.
What FDA clearance means for a sensor like this
A 510(k) clearance is not a claim that the device diagnoses concussion. It is a determination of substantial equivalence — same intended use, comparable technological characteristics and safety profile as a predicate. For an adjunctive assessment aid, that distinction is the entire scope of what the company can say. The device may not independently rule a concussion in or out; it may provide information a trained clinician interprets alongside everything else they know about the patient. That is a narrower, more honest claim than the headline version, and it is exactly the claim the 510(k) pathway is built to police.
This restraint is a feature of how consumer-adjacent neuro devices reach the market. Eye-tracking is increasingly cheap and ubiquitous — it is in headsets, phones, and driver-monitoring systems. The hard part is not capturing eye movement; it is establishing that a particular pattern means something clinically and then convincing the FDA your device measures it as safely and effectively as a predicate. The EyeBOX SNAP clearance is evidence that Oculogica cleared that bar again, in a category where the underlying sensing technology is becoming commonplace but the clinical validation remains the scarce asset.
It is worth dwelling on why that asymmetry — cheap sensor, expensive validation — defines the whole category. The cost of an eye-tracking camera has collapsed to the point where it is a commodity component, available off the shelf to any hardware team. What has not collapsed is the cost of demonstrating that the resulting data carries clinical meaning. That requires study populations, comparison against a predicate, and the documentation to satisfy a regulatory reviewer. The result is a market where the barrier to entry is not the hardware but the evidence file behind it. A startup can build an eye tracker in a weekend; it cannot build a 510(k) clearance in a weekend. The EyeBOX SNAP's value lives in the part you cannot rush, and the K-number is the proof that Oculogica did not skip it. Companies that try to short-circuit that validation either never clear the FDA or end up the subject of an enforcement action — the two outcomes the 510(k) gate exists to produce.
The consumer-tech angle
Eye-tracking is the connective tissue here. The same gaze-sensing technology that lets a VR headset render foveated graphics or a phone unlock by looking at it is, in a different package and with a very different evidence burden, a concussion sensor. That convergence is the consumer-tech story. As eye-tracking hardware spreads through ordinary devices, the question becomes which gaze signals carry clinical meaning and who has done the work to prove it. Oculogica's answer is a cleared device with a neurology product code and a predicate behind it — the credentials a phone's eye-unlock feature will never need and a medical device cannot ship without.
For sports medicine, emergency departments, and eventually anywhere a head injury is suspected, an objective, sensor-based aid is appealing precisely because it counters the subjectivity that has dogged concussion care. A device cannot want to return to play. The EyeBOX SNAP does not remove the clinician from the loop — the filing name guarantees that — but it adds a quantified input where there was none. In a category where the sensing hardware is racing toward commodity status, the moat is the regulatory record. K254086 is that record, and it is the difference between a gaze tracker and a cleared concussion assessment aid.